Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By

Drug Lowers Parkinson’s ‘Off’ Time in Phase 3 Trial

Written by Ted Samson
Posted on November 20, 2026

An experimental Parkinson’s disease treatment called solengepras reduced daily “off” time by about 37 minutes compared with a placebo (inactive treatment) in a phase 3 clinical trial. “Off” time refers to periods when Parkinson’s symptoms return or worsen as medication wears off.

The findings suggest that solengepras could become another treatment option for people who experience motor fluctuations (changes in movement symptoms) despite taking levodopa with or without other Parkinson’s medications.

However, solengepras is not yet approved by the U.S. Food and Drug Administration (FDA). More research and regulatory review are needed.

🗳️ Have you noticed “off” time — when symptoms return as medication wears off — with Parkinson’s?
Yes, often
Yes, occasionally
No, I haven’t noticed this
I’m not sure if my symptoms are “off” time

What Is Solengepras?

Solengepras is an experimental once-daily oral medication being studied as an add-on treatment for people with Parkinson’s disease who experience “off” periods. Unlike treatments that directly affect dopamine, solengepras blocks a receptor called GPR6. GPR6 is involved in brain pathways that control movement.

Many Parkinson’s medications work by replacing, boosting, or acting like dopamine, a chemical that helps control movement. Over time, the effects of each dose of levodopa may not last as long, leading to “off” periods when symptoms return.

During “on” periods, medication helps control movement symptoms. During “off” periods, symptoms such as slowness, stiffness, tremor, freezing, fatigue, or anxiety may return. These changes can make everyday activities more difficult.

What Did the Clinical Trial Find?

The phase 3 ARISE trial was an international study involving 341 adults with Parkinson’s disease who experienced motor fluctuations despite taking their usual medications. Participants had an average of 5.65 hours of daily “off” time when the study began.

Participants were randomly assigned to receive 75 milligrams or 150 milligrams of solengepras, or a placebo once daily for 12 weeks. Neither participants nor researchers knew which treatment each person received during the study.

The higher dose met the study’s main goal of reducing daily “off” time.

At week 12, researchers found:

Less “off” time — Daily “off” time decreased by 1.56 hours in the 150-milligram group, compared with 0.95 hours in the placebo group, a difference of approximately 37 minutes.
More “on” time — Time spent “on” without troublesome dyskinesia increased by about 36 minutes compared with placebo. Dyskinesia refers to involuntary movements that can occur during Parkinson’s treatment.
Better daily movement function — People receiving the higher dose had a 1.91-point greater improvement than those receiving placebo on a scale measuring how movement symptoms affect everyday activities.

The reduction in “off” time appeared as early as week 2, the first follow-up assessment.

Although the findings are encouraging, they haven’t yet been confirmed through a published, peer-reviewed phase 3 study.

What Were the Side Effects?

Like all treatments, solengepras can cause side effects (also called adverse events).

The most frequently reported adverse events among people receiving 150 milligrams included:

Headache
Urinary tract infection
Insomnia
Nausea

Some people also experienced dyskinesia.

Across all three treatment groups, 3.5 percent of participants stopped treatment because of an adverse event. No serious adverse events were reported in the 150-milligram group.

These findings provide an early picture of the medication’s safety. But the 12-week trial can’t establish its long-term risks.

What Could These Findings Mean for People With Parkinson’s Disease?

For people living with Parkinson’s disease, even relatively short periods of worsening symptoms can disrupt daily routines. The trial suggests that reducing “off” time by about half an hour compared with placebo may offer meaningful relief for some people.

However, the findings have important limitations. The trial lasted only 12 weeks and involved people who already experienced substantial daily “off” time despite taking Parkinson’s medications. It’s not yet clear how well solengepras might work for other groups or how its safety and effectiveness might change with longer use.

The drug’s developer, Cerevance, plans to discuss a potential New Drug Application with the FDA, but solengepras remains investigational.

For now, people experiencing “off” periods can work with their healthcare teams to explore existing ways to manage symptoms. Keeping track of when symptoms occur and how they relate to medication timing may help identify patterns and guide treatment discussions.

If you’re living with Parkinson’s disease and aren’t satisfied with how well your current treatment controls symptoms, or you’re curious about other options, talk with your neurologist about which approaches might best fit your symptoms, needs, and goals.

Share this article
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
175,835 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
175,835 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In

Thank you for subscribing!

Become a member to get even more

See answer